Compulsory licensing of pharmaceuticals : a review of Section 41 of the Patent Act.: RG15-2/1983E-PDF ; RG15-2/1983-PDF
"This paper reviews the effect of the 1969 Patent Act revisions on the drug industry in Canada. It analyzes how these changes have affected the activities of the pharmaceutical industry, the prices of prescription drugs and the current investment climate in Canada. It also considers, in line with government policy to stimulate high technology industry, a number of possible changes to the Patent Act that may improve the investment climate for major pharmaceutical firms while assuring a continued supply of reasonably priced drugs for Canadians"--Introduction, page 1.
Permanent link to this Catalogue record:
|Department/Agency||Canada. Consumer and Corporate Affairs Canada, issuing body.|
|Title||Compulsory licensing of pharmaceuticals : a review of Section 41 of the Patent Act.|
|Other language editions||[French]|
|Note(s)|| Issued also in French under title: Octroi obligatoire de licences dans le domaine des produits pharmaceutiques : révision de l'article 41 de la Loi sur les brevets. |
Digitized edition from print [produced by Innovation, Science and Economic Development Canada].
Includes bibliographical references.
|Publishing information|| [Ottawa] : Consumer and Corporate Affairs Canada = Consommation et corporations Canada, 1983. |
|Description||1 online resource (ix, 64 pages) : illustrations|
|Catalogue number|| |
|Subject terms|| Canada. Patent Act. |
Pharmaceutical industry -- Canada.
Drugs -- Prices -- Canada.
Compulsory licensing of patents -- Canada.
Request alternate formatsTo request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.
- Date modified: